Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations. J Vasc Interv Radiol 2014 Mar;25(3):365-9
Date
03/04/2014Pubmed ID
24581461DOI
10.1016/j.jvir.2013.11.027Scopus ID
2-s2.0-84896806046 (requires institutional sign-in at Scopus site) 53 CitationsAbstract
Transcatheter hepatic arterial administration of irinotecan-loaded drug-eluting beads (DEBIRI) is used to treat liver-only or liver-dominant metastatic disease from colorectal cancer (CRC). Eligibility for DEBIRI should be established in each individual patient by a multidisciplinary team based on comprehensive clinical, imaging, and laboratory assessment. Standardization of DEBIRI technique and protocols would be expected to lead to improved efficacy and safety. The present article provides a set of technical recommendations for the use of DEBIRI in the treatment of hepatic CRC metastases.
Author List
Lencioni R, Aliberti C, de Baere T, Garcia-Monaco R, Narayanan G, O'Grady E, Rilling WS, Walker D, Martin RCAuthor
William S. Rilling MD, FSIR Vice Chair, Professor in the Radiology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
CamptothecinChemoembolization, Therapeutic
Colorectal Neoplasms
Delayed-Action Preparations
Dose-Response Relationship, Drug
Drug Therapy
Drug-Eluting Stents
Humans
Injections, Intra-Arterial
Internationality
Liver Neoplasms
Practice Guidelines as Topic
